Tibet Weixinkang Medicine Co., Ltd.

Shanghai Stock Exchange 603676.SS

Tibet Weixinkang Medicine Co., Ltd. Price to Book Ratio (P/B) on January 14, 2025: 3.04

Tibet Weixinkang Medicine Co., Ltd. Price to Book Ratio (P/B) is 3.04 on January 14, 2025, a -4.88% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Tibet Weixinkang Medicine Co., Ltd. 52-week high Price to Book Ratio (P/B) is 3.54 on November 07, 2024, which is 16.45% above the current Price to Book Ratio (P/B).
Tibet Weixinkang Medicine Co., Ltd. 52-week low Price to Book Ratio (P/B) is 2.13 on February 07, 2024, which is -29.86% below the current Price to Book Ratio (P/B).
Tibet Weixinkang Medicine Co., Ltd. average Price to Book Ratio (P/B) for the last 52 weeks is 2.80.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

Shanghai Stock Exchange: 603676.SS

Tibet Weixinkang Medicine Co., Ltd.

CEO	Mr. Yong Zhang
IPO Date	July 21, 2017
Location	China
Headquarters	Building 4
Employees	701
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Tibet Weixinkang Medicine Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company's products include parenteral nutrition vitamins, electrolyte supplements, intravenous iron supplements, antibiotics, and medicine for digestive system and liver diseases. It also offers injection multivitamins, potassium magnesium aspartate for injection, iron sucrose injection, potassium aspartate injection, etc. The company was formerly known as Weixinkang Medicine Youxian Gongsi and changed its name to Tibet Weixinkang Medicine Co., Ltd. in 2015. Tibet Weixinkang Medicine Co., Ltd. was founded in 2006 and is based in Lhasa, China.

Key trends

Past 5 years